The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R
1
, R
2
, R
4
and R
5
are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof
isopropyl cations has been studied in the gasphase by a combination of chemical ionization (CI) mass spectrometry with a radiolytic approach. In particular, the reactivity of m- and p-bromofluorobenzene and of m- and p-chlorofluorobenzene has been investigated in propane gas at 50–720 Torr and 37.5°C, measuring the substrate and positional selectivity of the alkylation, and compared with condensed-phase
The present invention refers to novel ruthenium- and osmium-based catalysts for olefin metathesis reactions, particularly to catalysts having stereoselective properties. Z-selectivity is obtained by utilising two mono-anionic ligands of very different steric requirement. In olefin metathesis reactions these catalysts selectively provide the Z-isomer of disubstituted olefinic products even in presence of air or of acids.
2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF
申请人:Beijing Scitech-MQ Pharmaceuticals Limited
公开号:EP3686197A1
公开(公告)日:2020-07-29
The present disclosure relates to a novel compound as a JAK inhibitor, a composition, and an application thereof. Specifically, the present disclosure provides a compound having high AK inhibitory activity (as represented by formula (I)) or its isomer, solvate, hydrate, pharmaceutically-acceptable salt, and prodrug, and a pharmaceutical composition containing the compound. Also disclosed is an application of the present compound or pharmaceutical composition in preparation of a drug, and the drug is used for treating autoimmune diseases or cancers.
本公开涉及一种作为 JAK 抑制剂的新型化合物、一种组合物及其应用。具体而言,本公开提供了一种具有高 AK 抑制活性的化合物(如式 (I) 所示)或其同分异构体、溶解物、水合物、药学上可接受的盐和原药,以及含有该化合物的药物组合物。还公开了本化合物或药物组合物在制备药物中的应用,该药物用于治疗自身免疫性疾病或癌症。
2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
申请人:BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
公开号:US11344549B2
公开(公告)日:2022-05-31
The present disclosure relates to a novel compound as a JAK inhibitor, a composition, and an application thereof. Specifically, the present disclosure provides a compound having high JAK inhibitory activity (as represented by formula (I)) or its isomer, solvate, hydrate, pharmaceutically-acceptable salt, and prodrug, and a pharmaceutical composition containing the compound. Also disclosed is a use of the present compound or pharmaceutical composition in preparation of a medicament for treating autoimmune diseases or cancers.
本公开涉及一种作为 JAK 抑制剂的新型化合物、一种组合物及其应用。具体而言,本公开提供了一种具有高 JAK 抑制活性的化合物(如式 (I) 所示)或其异构体、溶解物、水合物、药学上可接受的盐和原药,以及含有该化合物的药物组合物。还公开了本化合物或药物组合物在制备治疗自身免疫性疾病或癌症的药物中的用途。